JP2019511527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511527A5 JP2019511527A5 JP2018553364A JP2018553364A JP2019511527A5 JP 2019511527 A5 JP2019511527 A5 JP 2019511527A5 JP 2018553364 A JP2018553364 A JP 2018553364A JP 2018553364 A JP2018553364 A JP 2018553364A JP 2019511527 A5 JP2019511527 A5 JP 2019511527A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- alkyl
- muscle
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCCc1cc(*)ccc1-c1ncc(*)[n]1Cc1cc(*)ccc1OCCC[C@](CC(O)=O)N Chemical compound CCCc1cc(*)ccc1-c1ncc(*)[n]1Cc1cc(*)ccc1OCCC[C@](CC(O)=O)N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322017P | 2016-04-13 | 2016-04-13 | |
| US62/322,017 | 2016-04-13 | ||
| PCT/US2017/027327 WO2017180818A1 (en) | 2016-04-13 | 2017-04-13 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511527A JP2019511527A (ja) | 2019-04-25 |
| JP2019511527A5 true JP2019511527A5 (https=) | 2020-06-18 |
| JP6925367B2 JP6925367B2 (ja) | 2021-08-25 |
Family
ID=58606595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553364A Active JP6925367B2 (ja) | 2016-04-13 | 2017-04-13 | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11358954B2 (https=) |
| EP (1) | EP3442948B1 (https=) |
| JP (1) | JP6925367B2 (https=) |
| KR (1) | KR102430906B1 (https=) |
| CN (1) | CN109071459B (https=) |
| BR (1) | BR112018069930B1 (https=) |
| ES (1) | ES2861503T3 (https=) |
| MX (1) | MX380531B (https=) |
| RU (1) | RU2746602C2 (https=) |
| WO (1) | WO2017180818A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102667386B1 (ko) | 2015-10-07 | 2024-05-21 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
| BR112018069930B1 (pt) | 2016-04-13 | 2024-02-20 | Mitobridge, Inc | Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica |
| PL3523283T3 (pl) | 2016-10-05 | 2021-12-13 | Mitobridge, Inc. | Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN113912547B (zh) | 2020-07-10 | 2024-04-30 | 成都凡诺西生物医药科技有限公司 | 取代苯丙咪唑类衍生物及其应用 |
| CN112479921B (zh) * | 2020-12-04 | 2022-12-06 | 中国药科大学 | 具有PPARδ激动活性的化合物、药物组合物及医药用途 |
| EP4015623A1 (en) | 2020-12-17 | 2022-06-22 | Universite De Montpellier | Pre-treatment of msc with ppar beta/delta agonist for treatment of ischemia-reperfusion injury |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
| DE4123341A1 (de) | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| WO2000050391A1 (en) | 1999-02-26 | 2000-08-31 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| PL361054A1 (en) * | 2000-08-17 | 2004-09-20 | Pfizer Inc. | Substituted imidazoles as tafia inhibitors |
| WO2004020408A1 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| JP4691988B2 (ja) | 2002-10-03 | 2011-06-01 | 小野薬品工業株式会社 | Ｌｐａ受容体拮抗剤 |
| WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
| WO2005030185A2 (en) | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
| JP2008512364A (ja) | 2004-09-06 | 2008-04-24 | エフ．ホフマン−ラ ロシュ アーゲー | ４−アミノメチルベンズアミジン誘導体及び第ＶＩＩａ因子阻害剤としてのその使用 |
| BRPI0606997A2 (pt) | 2005-02-15 | 2009-07-28 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa) e utilização dos compostos |
| KR20080042170A (ko) | 2005-09-07 | 2008-05-14 | 플렉시콘, 인코퍼레이티드 | Ｐｐａｒ 활성 화합물 |
| BRPI0707338A2 (pt) * | 2006-01-30 | 2011-05-03 | Transtech Pharma Inc | derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase |
| EP2001851A2 (en) | 2006-03-28 | 2008-12-17 | Novartis AG | Amide derivatives and their application for the treament of g protein related diseases |
| CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| CN101085772A (zh) | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| US20100063041A1 (en) | 2007-03-07 | 2010-03-11 | Ho-Sang Moon | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| JP2008285452A (ja) * | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
| CA2710764A1 (en) | 2007-12-28 | 2009-07-09 | The Salk Institute For Biological Studies | Methods for enhancing muscle performance and tone |
| AU2014247953A1 (en) | 2013-04-05 | 2015-11-12 | Mitobridge, Inc. | PPAR agonists |
| EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| US20170305894A1 (en) | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| KR102667386B1 (ko) | 2015-10-07 | 2024-05-21 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
| BR112018069930B1 (pt) | 2016-04-13 | 2024-02-20 | Mitobridge, Inc | Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica |
| BR112019005539A2 (pt) * | 2016-10-05 | 2019-06-18 | Mitobridge, Inc. | métodos de tratamento de lesão renal aguda |
-
2017
- 2017-04-13 BR BR112018069930-6A patent/BR112018069930B1/pt active IP Right Grant
- 2017-04-13 RU RU2018137521A patent/RU2746602C2/ru active
- 2017-04-13 WO PCT/US2017/027327 patent/WO2017180818A1/en not_active Ceased
- 2017-04-13 ES ES17718784T patent/ES2861503T3/es active Active
- 2017-04-13 KR KR1020187031232A patent/KR102430906B1/ko active Active
- 2017-04-13 JP JP2018553364A patent/JP6925367B2/ja active Active
- 2017-04-13 MX MX2018012538A patent/MX380531B/es unknown
- 2017-04-13 CN CN201780023617.7A patent/CN109071459B/zh active Active
- 2017-04-13 US US16/092,232 patent/US11358954B2/en active Active
- 2017-04-13 EP EP17718784.6A patent/EP3442948B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511527A5 (https=) | ||
| JP2020512298A5 (https=) | ||
| RU2018137521A (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| JP2019529516A5 (https=) | ||
| RU2019110736A (ru) | Кристаллические и солевые формы соединений агонистов ppar | |
| HRP20210887T1 (hr) | Inhibitori poli-adp riboza polimeraze (parp) | |
| US10968172B2 (en) | USP30 inhibitors | |
| JP2013516501A5 (https=) | ||
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP5701308B2 (ja) | 新規血管漏出遮断剤 | |
| EP3069612A2 (en) | Dithiol compounds, derivatives, and uses therefor | |
| JP2018508569A5 (https=) | ||
| EP3209732B1 (en) | Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders | |
| JP2016516068A5 (https=) | ||
| TW201943705A (zh) | 過氧化物酶體增生劑活化之受體（ppar）促效劑其化合物其醫藥組合物及其使用方法 | |
| JP2020503332A5 (https=) | ||
| CN111712489A (zh) | 用于治疗神经肌肉病症的化合物 | |
| Hnik et al. | Antisense oligonucleotide therapy in diabetic retinopathy | |
| IL259381A (en) | Mirabegron for the treatment of retinal diseases | |
| CN114008012A (zh) | 用于治疗神经肌肉病症的化合物 | |
| US10758511B2 (en) | Stable analogs of CYP450 lipid metabolites and inhibitors of soluble epoxide hydrolase | |
| WO2016001682A1 (en) | Treatment of hypertransaminasemia | |
| CN105073109A (zh) | 眼部疾病用治疗剂 | |
| TH1901003991A (th) | สารยับยั้งของ พอลิ-adp ไรโบส พอลิเมอเรส (parp) | |
| TW202537626A (zh) | 含磷ｂｃｌ抑制劑及抗衰老化合物及其用途 |